Using FACS, compared to control, increased ratios of CD8+ T-cells were also observed in the STING treated UPS tumors seven days after treatment, while the quantity of CD4+ T-cells remained stable across all time points (Figure 5E). This evidence concerns the gene STING1 and undifferentiated pleomorphic sarcoma.